Meaning
A contractual covenant permitting shareholders to inject fresh capital into a company to prevent or remedy a financial covenant breach under a credit agreement is known as equity cure rights. This mechanism functions as a contractual safety valve allowing equity holders to override a technical default by supplementing the borrower cash reserves before lenders accelerate the debt. Financing agreements define the frequency, timing limitations, and monetary caps governing such contributions, restricting how often a borrower may deploy this option during the life of a loan.
Contractual boundaries usually prohibit consecutive cures in adjacent quarters, forcing management to address operational deficits rather than relying indefinitely on shareholder injections.
Capital Injection
Investors transfer liquid funds directly to the corporate bank account within a specified grace period following the measurement date of the breached ratio. This transaction inflates the denominator of the leverage calculation or adds to earnings before interest, taxes, depreciation, and amortization depending on the precise formulation agreed upon at closing. Such capital infusions cost founders equity dilution and board leverage because new shares or convertible instruments must be issued hastily to the participating parties under duress.
Default Prevention
Preventing formal default notices spares the enterprise from punitive penalty interest rates and potential cross-default triggers across other commercial liabilities. Creditors relinquish the immediate right to demand full repayment when the cash injection restores compliance with the mandatory financial metrics before the statutory cure period expires. Exercising this option signals underlying operational strain to the lending syndicate, which frequently results in heightened monitoring and stricter future reporting requirements.
Valuation Impact
Negotiating these provisions during term sheet drafting requires founders to weigh the future cost of dilution against the probability of hitting a temporary financial trough. Valuation terms attached to emergency equity issues are rarely favorable to existing common holders, since investors providing rescue capital command severe pricing concessions. Prudent founders model worst-case downside scenarios to ensure that the aggregate cap on permitted cures aligns realistically with the projected cash burn of the business.